Joan Mancuso
@joanmancusombc.bsky.social
#PatientAdvocate living with #metastaticbreastcancer since 2007 (treatment pause since 2020). Always supporting the patient voice. Presenter, panelist and author for #breastcancer.
Medicare Open Enrollment is right around the corner! Sign up for our free webinar on October 13 to learn strategies for comparing plans, practical tips for choosing coverage, and what’s changing with Medicare in 2027. #CanSky Register today: TriageCancer.org/Webinars
Their success shows that it’s possible to count every death within days, find the cause of most, and use that data to make public health decisions. Other countries can follow their lead. substack.com/@tomfrieden/...
To Make Every Life Count, Count Every Life
What Rwanda can teach the world about measuring health
substack.com
Public health starts with two questions: what’s killing people, and what can stop these killers? Rwanda created a system to answer these questions.
Estrogen-only menopausal hormone therapy may reduce the risk of Alzheimer’s disease in women, according to a new study by Stanford Medicine investigators. stan.md/4g327iE
Study ties estrogen-based menopausal hormone therapy to lower Alzheimer’s risk
Some studies have reported that menopausal hormone therapy raises dementia risk. A new study that analyzed Alzheimer’s-disease hallmarks in autopsied brains indicates the opposite.
stan.md
Dr. Nora Disis, CVI Director, is a lead author of a new review article published by @jama.com. The review explores the science behind cancer vaccines and the field’s shifting focus toward preventive approaches. Read more: www.uwcvi.org/post/dr-disi... #CancerVaccines #CancerResearch
My caffeinated beverage of choice is iced tea, thanks to my time working in Dallas. If yours is energy drinks, you might want to reconsider your choice, according to the American Heart Association. My latest for @jama.com:
JAMA@jama.com · 3w ago#MedNews: Could #caffeine be good for the cardiovascular system? ☕🫀 It depends, according to a recent scientific statement from @americanheart.bsky.social. Here’s the latest evidence:
#ASTRO26 draws 10,000+ healthcare professionals from around the world. @washumedicine.bsky.social radiation oncologists at Siteman Cancer Center will be among the most prominent voices in the room.
WashU Medicine Radiation Oncologists at Siteman Cancer Center to Showcase Findings at ASTRO 2026
From Phase III prostate cancer trials to first-in-human adaptive radiotherapy, Siteman Cancer Center will highlight major advances at the 68th ASTRO Annual…
siteman.washu.edu
Dana-Farber researchers in collaboration with 23andMe identified a rare genetic risk factor for lung cancer in people who have never smoked. The findings could help shape future screening strategies for people who carry the EGFR mutation. Read more in the @nytimes.com.
This Rare Gene Drastically Raises Lung Cancer Risk in People Who Never Smoked
The gene is found predominantly in Southern Appalachia and may be one of the most powerful cancer-risk mutations ever found.
bit.ly
#AFibAwarenessMonth: Explore #CardioSmart’s #AFib Resource Hub for patient-friendly resources on symptoms, treatment options, medications and self-management strategies. Share these resources to help patients make informed care decisions ➡️ https://bit.ly/4x4rQNY #CardioSky
#AFibAwarenessMonth: Explore #CardioSmart’s #AFib Resource Hub for patient-friendly resources on symptoms, treatment options, medications and self-management strategies. Share these resources to help patients make informed care decisions ➡️ https://bit.ly/4x4rQNY #CardioSky
At #ASTRO26, UT MD Anderson faculty will present nearly 70 abstracts that showcase the latest research focused on improving outcomes and quality of life for cancer patients undergoing radiation therapy. Learn more: spr.ly/6049BGlqoR #EndCancer
UT MD Anderson at ASTRO
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, UT MD Anderson experts showcase their pacesetting research and join colleagues for discussion on the latest advances in radiation oncology.
spr.ly
In patients with #AFib and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results and Research Summary: https://nej.md/4ii61XB #ESCCongress
🔊Join the growing global ASCO PallOnc COP as we kick off the year nurturing old and new connections while gearing up for another successful year. DM for the zoom meeting link and to join our listserv. 🕒We can't wait to greet you all on Sep 29, 2026 @ 16:00 EST.
Exciting day for cancer care in Delaware! Senate Bill 120 expanding insurance coverage for #BiomarkerTesting was signed into law! TY to the legislators, advocacy organizations & most importantly patient advocates for sharing their stories 🧬🩺❤️!
Federal investment in #cancer #ClinicalTrials matters. A recent study found that federally funded trials are more likely to examine rare & pediatric cancers, prevention strategies, supportive care, & ways to reduce treatment burden. More via @theaacr.bsky.social's blog: bit.ly/4zS7fzm
Unboxing Cancer News, August 2026: Fishy Cancer, Federal- vs. Industry-funded Trials, and More
The August 2026 edition of “Unboxing Cancer News” highlights a transmissible cancer, federal- vs. industry-funded clinical trials, and more.
bit.ly
🩺 In Japan, elective #AtrialFibrillation ablation was associated with low in-hospital mortality during a decade of rapid expansion, with no evidence that broader adoption reduced procedural safety. #ESCCongress ja.ma/4qEw6SO
Fred Hutch Cancer Center’s Lynn Symonds, MD, who researches and treats #breastcancer, received a prestigious American Society of Clinical Oncology Career Development Award for work on a new biomarker for triple-negative breast cancer. Read more: https://bit.ly/3UZAGzd
OBS Neuroimmunology Webinar — August 27 Somatic mutations reveal the ontogeny of microglia in human aging (Nature 2026) *Speaker: Julia Belk (Stanford University) @juliabelk.bsky.social @stanfordmedicine.bsky.social Moderator: @asalboix.bsky.social *Zoom link: us02web.zoom.us/meeting/regi...
Updated Guideline: Breast Cancer Follow-Up & Surveillance New recommendations feature a risk-based approach to care, offering virtual or in-person visits, routine mammography, & tailored surveillance for high-risk patients. Read the updated guideline: https://bit.ly/4gqKJ7C
The US National Science Foundation will award about 30% fewer new research grants this fiscal year than in the last one, Nature has learnt. go.nature.com/3UcGoNW
Exclusive: NSF set to issue lowest number of new grants in four decades
The US science-funding agency is withholding $1 billion of its budget so that the money can go to a special White House project.
go.nature.com
Our August issue is live!🏖️ Featuring copper dependency in AML, iron-mediated ferroptosis, GPNMB-directed CAR-T cell therapy, IDH1-mutant vaccine in phase 1 trial, and more 🔗 nature.com/natcancer/vo...
personalized mrna cancer vaccines just hit phase 3 success for melanoma in 1,137 patients. combined with keytruda, it significantly reduced recurrence. this is the first late-stage win for individualized mrna therapy.
Personalized mRNA Cancer Vaccine Shows Success in Phase 3 Melanoma Trial
A personalized mRNA cancer vaccine, developed by Moderna and Merck, significantly reduced the risk of recurrence and spread of high-risk melanoma in a large-scale Phase 3 clinical trial. This breakthr
gavi.org
OBS Neuroimmunology Webinar — August 27 Somatic mutations reveal the ontogeny of microglia in human aging (Nature 2026) *Speaker: Julia Belk (Stanford University) @juliabelk.bsky.social @stanfordmedicine.bsky.social *Zoom link: us02web.zoom.us/meeting/regi...
In this short #BreastCancerBreakthroughs #ASCO2026 Highlight, Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the #HER2Climb-05 trial and how it impacts treatment for HER2+ #MetastaticBreastCancer. youtu.be/1DNsWW9s1t0?...
2026 ASCO Breast Cancer Highlights: HER2CLIMB-05 | Dana-Farber Cancer Institute
YouTube video by Dana-Farber Cancer Institute
youtu.be
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer. #bcsm #oncology www.onclive.com/view/europea...
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC | OncLive
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
onclive.com
The oral pan-RAS molecular glue ERAS-0015 has received @fda.gov fast track designation for the management of metastatic pancreatic adenocarcinoma. #pancsm #oncology www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma | OncLive
The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.
onclive.com
Join us for our first online AI for Biological Discovery Seminar, where our Chief AI Scientist Mihaela van der Schaar will host Caroline Uhler to discuss her research at the intersection of machine learning, statistics and genomics. Learn more and book your free ticket: https://bit.ly/4xAvNLL
AI in Biology Seminar | Professor Caroline Uhler
A new AI for Biological Discovery Seminar Series, presented by the Francis Crick Institute.
bit.ly
OBS Neuroimmunology Webinar — August 27 Somatic mutations reveal the ontogeny of microglia in human aging (Nature 2026) *Speaker: Julia Belk (Stanford University) @juliabelk.bsky.social @stanfordmedicine.bsky.social *Zoom link: us02web.zoom.us/meeting/regi...
